FDA Enhances Clinical Trials Amid Supreme Court Review of 'Skinny Labels'
The FDA is taking steps to accelerate clinical trials by reviewing data in real time, while the Supreme Court prepares to hear a pivotal case on 'skinny labels'.
Editorial Staff
1 min read
Updated 10 days ago
The FDA has announced an initiative aimed at speeding up the clinical trial process, which includes real-time data reviews.
This new approach involves pharmaceutical companies AstraZeneca and Amgen, who are participating in these enhanced trial processes.
Additionally, the Supreme Court is set to hear a significant case regarding the use of 'skinny labels', which could have implications for the pharmaceutical industry.